Novel therapies in multiple myeloma for newly diagnosed nontransplant candidates

Sigurdur Yngvi Kristinsson, Ola Landgren, Vincent S. Rajkumar

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


In the twenty-first century, melphalan-prednisone can no longer be regarded as the standard treatment of multiple myeloma patients not eligible for high-dose melphalan followed by autologous stem cell transplantation. The introduction of thalidomide, lenalidomide, and bortezomib has improved the arsenal of therapeutic options in multiple myeloma. Indeed, randomized studies have shown that melphalan-prednisone-thalidomide and melphalan-prednisone- bortezomib are superior to melphalan-prednisone alone. In addition, other combinations, including lenalidomide, are under study. In this review, we discuss the role of novel therapies in multiple myeloma in elderly multiple myeloma patients. Important aspects, such as toxicity and the role of prognostic factors, are also addressed.

Original languageEnglish (US)
Pages (from-to)473-478
Number of pages6
JournalCancer Journal
Issue number6
StatePublished - Nov 2009


  • Multiple myeloma
  • Prognosis
  • Therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Novel therapies in multiple myeloma for newly diagnosed nontransplant candidates'. Together they form a unique fingerprint.

Cite this